<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507751</url>
  </required_header>
  <id_info>
    <org_study_id>90/2009/IV</org_study_id>
    <nct_id>NCT03507751</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Meropenem During High-dose CRRT</brief_title>
  <official_title>Pharmacokinetics of Meropenem During High-dose Continuous Renal Replacement Therapy in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Warmia and Mazury in Olsztyn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Lublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of meropenem plasma concentration in critically ill patients who require CRRT
      (continuous renal replacement therapy). A standard dose of meropenem is administered, i.e. 1
      gram every 8 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational study performed on critically ill patients. Inclusion
      criteria are a severe infection on admission requiring the use of meropenem and CRRT.

      Both medical and surgical patients will be included. Any type of infections can be included
      (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes one-hour infusion of
      meropenem (1.0 gram) intravenously every 8 hours.

      Blood samples (2 mL) will be collected at the 15, 30, 45, 60, 75, 90, 120, 180, 240, and 480
      minutes after each dose of meropenem for 3 consecutive days. The standard arterial canula
      will be used to obtain samples.

      30 minutes after each sample collection, blood will be centrifuged for 10 minutes at 3,000
      rpms. Subsequently, supernatant will be collected and frozen.

      Serum meropenem concentration will be measured by high-performance liquid chromatography.

      Each patient's hemodynamic parameters will be recorded with the use of transpulmonary
      thermodilution technique (PICCO). Other therapies, i.e. ventilatory support, sedation, an
      antifungal agent will be given as required.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">February 2, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of meropenem</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Infection</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <description>Patients who require meropenem and CRRT during ICU (intensive care unit) stay</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>1.0 gram of meropenem given intravenously every 8 hours</description>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRRT</intervention_name>
    <description>Continuous renal replacement therapy for three days</description>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for obtaining meropenem concentrations
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Severely ill patients treated in ICU
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who require ICU treatment due to severe infection

          -  age 18-80 years

          -  an eligible consent obtained from the patient or his/her attendant

        Exclusion Criteria:

          -  allergy to meropenem

          -  lack of consent to participate in the study

          -  age of patients below 18 or above 80 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michał Borys, M.D., Ph.D.</last_name>
    <phone>+48506350569</phone>
    <email>michalborys1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mirosław Czuczwar, M.D., Ph.D.</last_name>
    <phone>+48 509390985</phone>
    <email>czuczwarm@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oddział Kliniczny Anestezjologii i Intensywnej Terapii, Wojewódzki Szpital Specjalistyczny w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <zip>10- 561</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Onichimowski, M.D., PhD.</last_name>
      <phone>+48 89 524 61 48</phone>
      <email>onichimowskid@wp.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2018</study_first_submitted>
  <study_first_submitted_qc>April 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>April 15, 2018</last_update_submitted>
  <last_update_submitted_qc>April 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lublin</investigator_affiliation>
    <investigator_full_name>Michał Borys</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

